DanCann Pharma A/S: Releases Q4-2024 report – Revenue (NET) up by 27.8% YoY and EBITDA up by 63.8% YoY
Read the article
DanCann Pharma A/S: Agreement Reached on Permanent Medicinal Cannabis Scheme in Denmark
Read the article
DanCann Pharma A/S: Number of Reported Suspected Adverse Reactions Drops by Two-Thirds in 2023 Despite 72% Growth in the Medicinal Cannabis Pilot Programme
Read the article

DanCann Pharma Pressroom:

We are DanCann Pharma.

We aspire to create value for society, our future business and shareholders.

Show all press releases on Cision
Subscribe to newsletter